Benjamin Bates
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin Bates has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Soko Setoguchi
Rutgers University Institute for Health, Healthcare Policy, and Aging Research New Brunswick New Jersey USA
6 shared publications - Vithal Madhira
Palila Software LLC, Reno, NV
5 shared publications - Feifan Liu
University of Massachusetts Chan Medical School, Worcester, USA
4 shared publications - Melanie Rua
Rutgers University Institute for Health, Healthcare Policy, and Aging Research
4 shared publications - Noha Sharafeldin
University of Alabama at Birmingham, Birmingham, AL
4 shared publications - Qianqian Song
University of Florida
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Springer Nature in BMC Primary Care
Primary care physicians on caring for patients with complex comorbidities and history of breast cancer
Background: There have been calls for primary care physicians (PCPs) to take a greater role in the care of their patients with a history of cancer; however, little is known about PCPs’ perspectives on integrating cancer survivorship recommendations into practice. We sought to understand the perspectives of PCPs in the United States on caring for patients with a history of breast cancer and multiple chronic conditions, breast cancer survivorship recommendations, and approaches to improve care for these patients. Methods: As part of a larger NCI-funded study, we iteratively interviewed and analyzed a purposeful sample of eight PCPs from diverse settings using qualitative, semi-structured interviews. We used a clinical vignette to ask participants about care for a hypothetical patient with multiple chronic conditions and a history of breast cancer, followed by questions about integrating breast cancer survivorship recommendations into routine practice, and potential solutions to obstacles. We used an editing organizing style of analysis to identify overarching patterns and themes across interviews. Results: Consistent themes emerged across eight interviews about PCPs’ perspectives on integrating care for patients with a history of cancer into practice: (1) PCPs perceive their role as providing whole-person, patient-centered care; (2) Most breast cancer survivorship recommendations are within the scope of primary care; (3) Delineation of roles and responsibilities in the care of cancer survivors is unclear; (4) PCPs rarely receive actionable and accessible information from oncology teams and must piece together information from multiple sources to make informed decisions. Conclusion: Poor delineation of roles and lack of actionable and accessible information hinder incorporating some aspects of survivorship into primary care practices. Local resources and actionable information may support better integration of survivorship care in primary care.
- 23 October 2026
- Published by Springer Nature in BMC Primary Care
Open AccessPrimary care physicians on caring for patients with complex comorbidities and history of breast cancer
Background: There have been calls for primary care physicians (PCPs) to take a greater role in the care of their patients with a history of cancer; however, little is known about PCPs’ perspectives on integrating cancer survivorship recommendations into practice. We sought to understand the perspectives of PCPs in the United States on caring for patients with a history of breast cancer and multiple chronic conditions, breast cancer survivorship recommendations, and approaches to improve care for these patients. Methods: As part of a larger NCI-funded study, we iteratively interviewed and analyzed a purposeful sample of eight PCPs from diverse settings using qualitative, semi-structured interviews. We used a clinical vignette to ask participants about care for a hypothetical patient with multiple chronic conditions and a history of breast cancer, followed by questions about integrating breast cancer survivorship recommendations into routine practice, and potential solutions to obstacles. We used an editing organizing style of analysis to identify overarching patterns and themes across interviews. Results: Consistent themes emerged across eight interviews about PCPs’ perspectives on integrating care for patients with a history of cancer into practice: (1) PCPs perceive their role as providing whole-person, patient-centered care; (2) Most breast cancer survivorship recommendations are within the scope of primary care; (3) Delineation of roles and responsibilities in the care of cancer survivors is unclear; (4) PCPs rarely receive actionable and accessible information from oncology teams and must piece together information from multiple sources to make informed decisions. Conclusion: Poor delineation of roles and lack of actionable and accessible information hinder incorporating some aspects of survivorship into primary care practices. Local resources and actionable information may support better integration of survivorship care in primary care.
- Open Access
- 27 April 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (5) , e70370
Identifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real‐World Data: A Scoping Review
Purpose: This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real‐world data (RWD). Methods: We conducted a scoping review of published, English‐language studies describing algorithms for identifying any LOTs with systemic anti‐cancer therapy (SACT) for either non‐metastatic or metastatic lung, breast, or colorectal cancer in RWD between January 1, 2014, and April 29, 2024. Dual reviewers independently screened titles, abstracts, and full‐text articles, with disagreements resolved by a third reviewer. Data were extracted, categorized, synthesized, and summarized in narrative and tabular formats. Results: The review identified 25 studies, mainly (64%) from the United States. Electronic health/medical records (EHRs) were the most frequently utilized (72%) RWD source. Twenty‐four studies (96%) described RWD algorithms for identifying the initiation of a new LOT for metastatic lung, breast, or colorectal cancer. In 23 studies, algorithms required observing a new, adjuvant, SACT after an “incident” metastatic diagnosis code, which had been preceded by a metastasis‐free lookback period of varied duration. Three studies' algorithms required observation of the completion of non‐metastatic LOTs before initiation of a new LOT for metastatic cancer. Three studies validated their algorithms. Conclusions: Different algorithms are being used to identify LOT initiation for metastatic cancer. Most algorithms require an incident diagnosis of metastasis before considering subsequent SACT as newly initiated LOT for metastatic cancer. However, definitions of metastasis onset and gap duration to therapy initiation vary.
- 27 April 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (5) , e70370
Open AccessIdentifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real‐World Data: A Scoping Review
Purpose: This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real‐world data (RWD). Methods: We conducted a scoping review of published, English‐language studies describing algorithms for identifying any LOTs with systemic anti‐cancer therapy (SACT) for either non‐metastatic or metastatic lung, breast, or colorectal cancer in RWD between January 1, 2014, and April 29, 2024. Dual reviewers independently screened titles, abstracts, and full‐text articles, with disagreements resolved by a third reviewer. Data were extracted, categorized, synthesized, and summarized in narrative and tabular formats. Results: The review identified 25 studies, mainly (64%) from the United States. Electronic health/medical records (EHRs) were the most frequently utilized (72%) RWD source. Twenty‐four studies (96%) described RWD algorithms for identifying the initiation of a new LOT for metastatic lung, breast, or colorectal cancer. In 23 studies, algorithms required observing a new, adjuvant, SACT after an “incident” metastatic diagnosis code, which had been preceded by a metastasis‐free lookback period of varied duration. Three studies' algorithms required observation of the completion of non‐metastatic LOTs before initiation of a new LOT for metastatic cancer. Three studies validated their algorithms. Conclusions: Different algorithms are being used to identify LOT initiation for metastatic cancer. Most algorithms require an incident diagnosis of metastasis before considering subsequent SACT as newly initiated LOT for metastatic cancer. However, definitions of metastasis onset and gap duration to therapy initiation vary.
- Open Access
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e043306
Exposure–Response to High PM 2.5 Levels for Cardiovascular Events in High‐Risk Older Adults in Taiwan
Background: Limited studies using individual‐level health outcome data exist from countries with a wider range of particulate matter with a diameter of 15 μg/m 3 PM 2.5 concentrations. Taiwan reduced PM 2.5 over time with its policies, which provide opportunities to illustrate the dose–response curves and how reductions of PM 2.5 over time correlated with cardiovascular events incidence in a nationwide sample. Methods: Using data from the 2009 to 2019 Taiwan National Health Insurance Database linked to nationwide PM 2.5 data, we examined the magnitude of the exposure–response curve between seasonal average PM 2.5 level and cardiovascular events‐related hospitalizations among older adults at high risk for cardiovascular events. We used history‐adjusted marginal structural models including potential confounding by individual demographic factors, baseline comorbidities, and health service measures. Results: We included 373 402 older adults with high‐risk conditions in Taiwan. Using the PM 2.5 concentration 23.5 μg/m 3 ) were associated with hazard ratio of 1.13 (95% CI, 1.09–1.18) and 1.19 (95% CI, 1.14–1.24), 1.07 (95% CI, 1.03–1.11) and 1.14 (95% CI, 1.10–1.18), 1.22 (95% CI, 1.08–1.38) and 1.31 (95% CI, 1.16–1.48), 1.04 (95% CI, 0.98–1.10) and 1.10 (95% CI, 1.04–1.16), respectively, for heart failure, ischemic stroke/transient ischemic attack, deep vein thrombosis, and myocardial infarction/acute coronary syndrome. Conclusions: Further lowering PM 2.5 levels beyond current regulatory standards (15 μg/m 3 ) may effectively reduce the incidence of heart failure, deep vein thrombosis, and ischemic stroke/transient ischemic attack, and can lead to tangible health benefits in the high‐risk older population.
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e043306
Open AccessExposure–Response to High PM 2.5 Levels for Cardiovascular Events in High‐Risk Older Adults in Taiwan
Background: Limited studies using individual‐level health outcome data exist from countries with a wider range of particulate matter with a diameter of 15 μg/m 3 PM 2.5 concentrations. Taiwan reduced PM 2.5 over time with its policies, which provide opportunities to illustrate the dose–response curves and how reductions of PM 2.5 over time correlated with cardiovascular events incidence in a nationwide sample. Methods: Using data from the 2009 to 2019 Taiwan National Health Insurance Database linked to nationwide PM 2.5 data, we examined the magnitude of the exposure–response curve between seasonal average PM 2.5 level and cardiovascular events‐related hospitalizations among older adults at high risk for cardiovascular events. We used history‐adjusted marginal structural models including potential confounding by individual demographic factors, baseline comorbidities, and health service measures. Results: We included 373 402 older adults with high‐risk conditions in Taiwan. Using the PM 2.5 concentration 23.5 μg/m 3 ) were associated with hazard ratio of 1.13 (95% CI, 1.09–1.18) and 1.19 (95% CI, 1.14–1.24), 1.07 (95% CI, 1.03–1.11) and 1.14 (95% CI, 1.10–1.18), 1.22 (95% CI, 1.08–1.38) and 1.31 (95% CI, 1.16–1.48), 1.04 (95% CI, 0.98–1.10) and 1.10 (95% CI, 1.04–1.16), respectively, for heart failure, ischemic stroke/transient ischemic attack, deep vein thrombosis, and myocardial infarction/acute coronary syndrome. Conclusions: Further lowering PM 2.5 levels beyond current regulatory standards (15 μg/m 3 ) may effectively reduce the incidence of heart failure, deep vein thrombosis, and ischemic stroke/transient ischemic attack, and can lead to tangible health benefits in the high‐risk older population.
- Open Access
- 24 November 2025
- Published by Wiley
Identifying the initiation of a new line of therapy for metastatic lung, breast, and colorectal cancer in real-world data: a scoping review
Purpose: This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real-world data (RWD). Methods: We conducted a scoping review of published, English-language studies describing algorithms for identifying any LOTs with systemic anti-cancer therapy (SACT) for either non-metastatic or metastatic lung, breast or colorectal cancer in RWD between January 1, 2014, and April 29, 2024. Dual reviewers independently screened titles, abstracts and full-text articles with disagreements resolved by a third reviewer. Data were extracted, categorized, synthesized, and summarized in narrative and tabular formats. Results: The review identified 25 studies, mainly from the U.S. (64%). Electronic health/medical records (EHRs) were the most frequently utilized (72%) RWD source. Twenty-four studies (96%) described RWD algorithms for identifying the initiation of a new LOT for metastatic lung, breast, or colorectal cancer. In 23 studies, algorithms required observing a new, adjuvant, SACT after an ‘incident’ metastatic diagnosis code, which had been preceded by a metastasis-free lookback period of varied duration. Three studies’ algorithms required observation of the completion of non-metastatic LOTs before initiation of a new LOT for metastatic cancer. Three studies validated their algorithms. Conclusions: Different algorithms are being used to identify LOT initiation for metastatic cancer. Most algorithms require an incident diagnosis of metastasis before considering subsequent SACT as newly initiated LOT for metastatic cancer. However, definitions of metastasis onset, and gap duration to therapy initiation, vary.
- 24 November 2025
- Published by Wiley
Open AccessIdentifying the initiation of a new line of therapy for metastatic lung, breast, and colorectal cancer in real-world data: a scoping review
Purpose: This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real-world data (RWD). Methods: We conducted a scoping review of published, English-language studies describing algorithms for identifying any LOTs with systemic anti-cancer therapy (SACT) for either non-metastatic or metastatic lung, breast or colorectal cancer in RWD between January 1, 2014, and April 29, 2024. Dual reviewers independently screened titles, abstracts and full-text articles with disagreements resolved by a third reviewer. Data were extracted, categorized, synthesized, and summarized in narrative and tabular formats. Results: The review identified 25 studies, mainly from the U.S. (64%). Electronic health/medical records (EHRs) were the most frequently utilized (72%) RWD source. Twenty-four studies (96%) described RWD algorithms for identifying the initiation of a new LOT for metastatic lung, breast, or colorectal cancer. In 23 studies, algorithms required observing a new, adjuvant, SACT after an ‘incident’ metastatic diagnosis code, which had been preceded by a metastasis-free lookback period of varied duration. Three studies’ algorithms required observation of the completion of non-metastatic LOTs before initiation of a new LOT for metastatic cancer. Three studies validated their algorithms. Conclusions: Different algorithms are being used to identify LOT initiation for metastatic cancer. Most algorithms require an incident diagnosis of metastasis before considering subsequent SACT as newly initiated LOT for metastatic cancer. However, definitions of metastasis onset, and gap duration to therapy initiation, vary.
- 20 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (21) , 4396-4404
Diversity by Design: Real-World Data to Enhance Representation in Clinical Cancer Research
Inclusive and diverse enrollment in clinical trials promotes trust in clinical research and its findings by improving generalizability and fostering health and health care equities. Diverse participation also facilitates the detection of potential differences in treatment response across subgroups, thereby enhancing precision medicine efforts. Yet, patients with cancer who participate in clinical trials are more likely to be Caucasian, younger, and healthier compared with their representation in the broader cancer population. Given emerging health authority guidance and other related initiatives calling for more representative trials, there is an urgent need to develop and implement strategies to improve enrollment of a study population that reflects the intended use population. Real-world data/evidence (RWD/E) can help set trial enrollment targets and strategy, identify drivers and barriers in recruiting diverse populations, and provide supplemental evidence on underrepresented populations, thus improving the external validity of clinical trial results. In this perspective review, we outline a diversity dimension framework that includes demographic, clinical, treatment environment, and other elements and discuss opportunities and challenges with which RWD/E could enhance clinical trial representativeness and diversity. Specifically, we discuss the diversity dimensions relevant to oncology clinical development and various approaches in utilizing RWD to improve diversity across stages of clinical development, with use cases.
- 20 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (21) , 4396-4404
Diversity by Design: Real-World Data to Enhance Representation in Clinical Cancer Research
Inclusive and diverse enrollment in clinical trials promotes trust in clinical research and its findings by improving generalizability and fostering health and health care equities. Diverse participation also facilitates the detection of potential differences in treatment response across subgroups, thereby enhancing precision medicine efforts. Yet, patients with cancer who participate in clinical trials are more likely to be Caucasian, younger, and healthier compared with their representation in the broader cancer population. Given emerging health authority guidance and other related initiatives calling for more representative trials, there is an urgent need to develop and implement strategies to improve enrollment of a study population that reflects the intended use population. Real-world data/evidence (RWD/E) can help set trial enrollment targets and strategy, identify drivers and barriers in recruiting diverse populations, and provide supplemental evidence on underrepresented populations, thus improving the external validity of clinical trial results. In this perspective review, we outline a diversity dimension framework that includes demographic, clinical, treatment environment, and other elements and discuss opportunities and challenges with which RWD/E could enhance clinical trial representativeness and diversity. Specifically, we discuss the diversity dimensions relevant to oncology clinical development and various approaches in utilizing RWD to improve diversity across stages of clinical development, with use cases.
- Open Access
- 8 July 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (5) , 3395-3405
Management and Outcomes of Heart Failure Hospitalization Among Older Adults in the United States and Japan
Aims: Despite advances in therapies, the disease burden of heart failure (HF) has been rising globally. International comparisons of HF management and outcomes may reveal care patterns that improve outcomes. Accordingly, we examined clinical management and patient outcomes in older adults hospitalized for acute HF in the United States (US) and Japan. Methods: We identified patients aged >65 who were hospitalized for HF in 2013 using US Medicare data and the Japanese Registry of Acute Decompensated Heart Failure (JROADHF). We described patient characteristics, management, and healthcare utilization and compared outcomes using multivariable Cox regression during and after HF hospitalization. Results: Among 11 193 Japanese and 120 289 US patients, age and sex distributions were similar, but US patients had higher comorbidity rates. The length of stay was longer in Japan (median 18 vs. 5 days). While Medicare patients had higher use of implantable cardioverter defibrillator or cardiac resynchronization therapy during hospitalization (1.32% vs. 0.6%), Japanese patients were more likely to receive cardiovascular medications at discharge and to undergo cardiac rehabilitation within 3 months of HF admission (31% vs. 1.6%). Physician follow-up within 30 days was higher in Japan (77% vs. 57%). Cardiovascular readmission, cardiovascular mortality and all-cause mortality were 2.1–3.7 times higher in the US patients. The per-day cost of hospitalization was lower in Japan ($516 vs. $1323). Conclusions: We observed notable differences in the management, outcomes and costs of HF hospitalization between the US and Japan. Large differences in length of hospitalization, cardiac rehabilitation rate and outcomes warrant further research to determine the optimal length of stay and assess the benefits of inpatient cardiac rehabilitation to reduce rehospitalization and mortality.
- 8 July 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (5) , 3395-3405
Open AccessManagement and Outcomes of Heart Failure Hospitalization Among Older Adults in the United States and Japan
Aims: Despite advances in therapies, the disease burden of heart failure (HF) has been rising globally. International comparisons of HF management and outcomes may reveal care patterns that improve outcomes. Accordingly, we examined clinical management and patient outcomes in older adults hospitalized for acute HF in the United States (US) and Japan. Methods: We identified patients aged >65 who were hospitalized for HF in 2013 using US Medicare data and the Japanese Registry of Acute Decompensated Heart Failure (JROADHF). We described patient characteristics, management, and healthcare utilization and compared outcomes using multivariable Cox regression during and after HF hospitalization. Results: Among 11 193 Japanese and 120 289 US patients, age and sex distributions were similar, but US patients had higher comorbidity rates. The length of stay was longer in Japan (median 18 vs. 5 days). While Medicare patients had higher use of implantable cardioverter defibrillator or cardiac resynchronization therapy during hospitalization (1.32% vs. 0.6%), Japanese patients were more likely to receive cardiovascular medications at discharge and to undergo cardiac rehabilitation within 3 months of HF admission (31% vs. 1.6%). Physician follow-up within 30 days was higher in Japan (77% vs. 57%). Cardiovascular readmission, cardiovascular mortality and all-cause mortality were 2.1–3.7 times higher in the US patients. The per-day cost of hospitalization was lower in Japan ($516 vs. $1323). Conclusions: We observed notable differences in the management, outcomes and costs of HF hospitalization between the US and Japan. Large differences in length of hospitalization, cardiac rehabilitation rate and outcomes warrant further research to determine the optimal length of stay and assess the benefits of inpatient cardiac rehabilitation to reduce rehospitalization and mortality.
- Open Access
Exposure-Response to High PM 2.5 Levels for Cardiovascular Events in High-risk Older Adults in Taiwan
Background: Multiple studies from countries with relatively lower PM 2.5 level demonstrated that acute and chronic exposure even at lower than recommended level, e.g., 9 μg/m 3 in the US increased the risk of cardiovascular (CV) events. However, limited studies using individual level data exist from countries with a wider range of PM levels to illustrate shape of the exposure-response curve throughout the range including > 20 μg/m 3 PM 2·5 concentrations. Taiwan with its policies reduced PM 2.5 over time provide opportunities to illustrate the dose response curves and how reductions of PM 2.5 over time correlated with CV events incidence in a nationwide sample. Methods: Using data from the 2009-2019 Taiwan National Health Insurance Database linked to nationwide PM2.5 data. We examined the shape and magnitude of the exposure-response curve between seasonal average PM 2·5 level and CV events-related hospitalizations among older adults at high-risk for CV events. We used history-adjusted marginal structural models including potential confounding by individual demographic factors, baseline comorbidities, and health service measures. To quantify the risk below and above 20 μg/m 3 we conducted stratified Cox regression. We also plotted PM 2.5 and CV events from 2009-2019 as well as average temperature as a comparison. Findings: Using the PM 2.5 concentration 23.5 μg/m 3 ) were associated with hazard ration of 1.13 (95%CI 1.09-1.18) and 1.19 (95%CI 1.14-1.24), 1.07 (95%CI 1.03-1.11) and 1.14 (95%CI 1.10-1.18), 1.22 (95%CI 1.08-1.38) and 1.31 (95%CI 1.16-1.48), 1.04 (95%CI 0.98-1.10) and 1.10 (95%CI 1.04-1.16) respectively for HF, IS/TIA,PE/DVT and MI/ACS. A nonlinear relationship between PM 2·5 and CV events outcomes was observed at PM 2·5 levels above 20 μg/m 3 . Interpretation: A nonlinear exposure-response relationship between PM2·5 concentration and the incidence of cardiovascular events exists when PM2.5 is higher than the levels recommended by WHO Air Quality Guidelines. Further lowering PM2·5 levels beyond current regulatory standards may effectively reduce the incidence of cardiovascular events, particularly HF and DVT, and can lead to tangible health benefits in high-risk elderly population.
Open AccessExposure-Response to High PM 2.5 Levels for Cardiovascular Events in High-risk Older Adults in Taiwan
Background: Multiple studies from countries with relatively lower PM 2.5 level demonstrated that acute and chronic exposure even at lower than recommended level, e.g., 9 μg/m 3 in the US increased the risk of cardiovascular (CV) events. However, limited studies using individual level data exist from countries with a wider range of PM levels to illustrate shape of the exposure-response curve throughout the range including > 20 μg/m 3 PM 2·5 concentrations. Taiwan with its policies reduced PM 2.5 over time provide opportunities to illustrate the dose response curves and how reductions of PM 2.5 over time correlated with CV events incidence in a nationwide sample. Methods: Using data from the 2009-2019 Taiwan National Health Insurance Database linked to nationwide PM2.5 data. We examined the shape and magnitude of the exposure-response curve between seasonal average PM 2·5 level and CV events-related hospitalizations among older adults at high-risk for CV events. We used history-adjusted marginal structural models including potential confounding by individual demographic factors, baseline comorbidities, and health service measures. To quantify the risk below and above 20 μg/m 3 we conducted stratified Cox regression. We also plotted PM 2.5 and CV events from 2009-2019 as well as average temperature as a comparison. Findings: Using the PM 2.5 concentration 23.5 μg/m 3 ) were associated with hazard ration of 1.13 (95%CI 1.09-1.18) and 1.19 (95%CI 1.14-1.24), 1.07 (95%CI 1.03-1.11) and 1.14 (95%CI 1.10-1.18), 1.22 (95%CI 1.08-1.38) and 1.31 (95%CI 1.16-1.48), 1.04 (95%CI 0.98-1.10) and 1.10 (95%CI 1.04-1.16) respectively for HF, IS/TIA,PE/DVT and MI/ACS. A nonlinear relationship between PM 2·5 and CV events outcomes was observed at PM 2·5 levels above 20 μg/m 3 . Interpretation: A nonlinear exposure-response relationship between PM2·5 concentration and the incidence of cardiovascular events exists when PM2.5 is higher than the levels recommended by WHO Air Quality Guidelines. Further lowering PM2·5 levels beyond current regulatory standards may effectively reduce the incidence of cardiovascular events, particularly HF and DVT, and can lead to tangible health benefits in high-risk elderly population.
- 1 May 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400024
Advancing Readership Needs of the Clinical Cancer Informatics Community
- 1 May 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400024
Advancing Readership Needs of the Clinical Cancer Informatics Community
- Open Access
- 11 April 2024
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 81, 1-9
Ambient heat exposure patterns and emergency department visits and hospitalizations among medicare beneficiaries 2008–2019
- 11 April 2024
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 81, 1-9
Open AccessAmbient heat exposure patterns and emergency department visits and hospitalizations among medicare beneficiaries 2008–2019
- 7 March 2024
- Published by Elsevier in Environmental Research
- Vol. 251 (Pt 1) , 118628
Air pollution and serious bleeding events in high-risk older adults
- 7 March 2024
- Published by Elsevier in Environmental Research
- Vol. 251 (Pt 1) , 118628
Air pollution and serious bleeding events in high-risk older adults